Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: Assessment of frequency and significance

Human Pathology

Volumn 44, Issue 8, 2013, Pages 1508-1515

  Fadare, Oluwole ^a,b   Liang, Sharon X ^c   Crispens, Marta A ^b   Jones III, Howard W ^b   Khabele, Dineo ^b   Gwin, Katja ^d   Zheng, Wenxin ^e   Mohammed, Khaled ^f   Parkash, Vinita ^g,h   Hecht, Jonathan L ⁱ   Desouki, Mohamed M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h BRIDGEPORT HOSPITAL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clear cell carcinoma; Endometrium; IMP3; Insulin like growth factor II mRNA binding protein

Indexed keywords

ONCOFETAL ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INFILTRATION; CANCER PROGNOSIS; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOARCHITECTURE; ENDOMETRIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; STATISTICAL SIGNIFICANCE; TUMOR INVASION;

CLEAR CELL CARCINOMA; ENDOMETRIUM; IMP3; INSULIN-LIKE GROWTH FACTOR-II MRNA-BINDING PROTEIN;

ADENOCARCINOMA, CLEAR CELL; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880332816     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.12.003     Document Type: Article

References (29)

1. F.C. Nielsen, J. Nielsen, and J. Christiansen A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking Scand J Clin Lab Invest Suppl 234 2001 93 99
2. N.A. Hammer, Hansen TO, and A.G. Byskov Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer Reproduction 130 2005 203 212
3. F.C. Nielsen, J. Nielsen, M.A. Kristensen, G. Koch, and J. Christiansen Cytoplasmic trafficking of IGF-II mRNA-binding protein by conserved KH domains J Cell Sci 115 Pt 10 2002 2087 2097
4. F. Müeller-Pillasch, U. Lacher, and C. Wallrapp Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein Oncogene 14 1997 2729 2733
5. J.J. Findeis-Hosey, and H. Xu The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology Hum Pathol 42 2011 303 314
6. M. Köbel, H. Xu, and P.A. Bourne IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype Mod Pathol 22 2009 469 475
7. D.A. Budwit-Novotny, K.S. McCarty, and E.B. Cox Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody Cancer Res 46 1986 5419 5425
8. O. Fadare, S.X. Liang, E.C. Ulukus, S.K. Chambers, and W. Zheng Precursors of endometrial clear cell carcinoma Am J Surg Pathol 30 2006 1519 1530
9. F. Moid, and K. Berezowski Pathologic quiz case: a 70-year-old woman with postmenopausal bleeding. Endometrial intraepithelial carcinoma, clear cell type Arch Pathol Lab Med 128 2004 e157 e158
10. S. Yamamoto, H. Tsuda, and H. Shimazaki Histological grading of ovarian clear cell adenocarcinoma: proposal for a simple and reproducible grouping system based on tumor growth architecture Int J Gynecol Pathol 31 2012 116 124
11. W. Zheng, X. Yi, and O. Fadare The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma Am J Surg Pathol 32 2008 304 315
12. Y. He, L. Li, and W. Jiang Expression of the insulin-like growth factor-II mRNA-binding protein 3 (IMP3) and carcinoembryonic antigen (CEA) in mucinous minimal deviation adenocarcinoma Pathol Res Pract 207 2011 295 299
13. C. Li, K.L. Rock, B.A. Woda, Z. Jiang, A.E. Fraire, and K. Dresser IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression Mod Pathol 20 2007 242 247
14. K. Cornejo, M. Shi, and Z. Jiang Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma Hum Pathol 43 2012 1567 1572
15. D. Lu, X. Yang, and N.Y. Jiang IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer Am J Surg Pathol 35 2011 1638 1645
16. C. Li, V. Zota, and B.A. Woda Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations Mod Pathol 20 2007 1263 1268
17. P. Mhawech-Fauceglia, F.R. Herrmann, and H. Rai IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma Am J Clin Pathol 133 2010 899 908
18. A. Alkushi, M. Köbel, S.E. Kalloger, and C.B. Gilks High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes Int J Gynecol Pathol 29 2010 343 350
19. O. Fadare, W. Zheng, and M.A. Crispens Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases Am J Cancer Res 2013 [in press]
20. M.A. Crozier, L.J. Copeland, E.G. Silva, D.M. Gershenson, and C.A. Stringer Clear cell carcinoma of the ovary: a study of 59 cases Gynecol Oncol 35 1989 199 203
21. S. Yamamoto, H. Tsuda, and H. Shimazaki Clear cell adenocarcinoma with a component of poorly differentiated histology: a poor prognostic subgroup of ovarian clear cell adenocarcinoma Int J Gynecol Pathol 30 2011 431 441
22. K. Yaniv, and J.K. Yisraeli The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis Gene 287 2002 49 54
23. Y.M. Jeng, C.C. Chang, and F.C. Hu RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma Hepatology 48 2008 1118 1127
24. R. Suvasini, B. Shruti, and B. Thota Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2 J Biol Chem 286 2011 25882 25890
25. B. Liao, Y. Hu, D.J. Herrick, and G. Brewer The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells J Biol Chem 280 2005 18517 18524
26. O. Kabbarah, C. Nogueira, and B. Feng Integrative genome comparison of primary and metastatic melanomas PLoS One 5 2010 e10770
27. S. Samanta, V.M. Sharma, A. Khan, and A.M. Mercurio Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer Oncogene 31 2012 4689 4697
28. J. Vikesaa, T.V. Hansen, and L. Jønson RNA-binding IMPs promote cell adhesion and invadopodia formation EMBO J 25 2006 1456 1468
29. B. Liao, Y. Hu, and G. Brewer RNA-binding protein insulin-like growth factor mRNA-binding protein 3 (IMP-3) promotes cell survival via insulin-like growth factor II signaling after ionizing radiation J Biol Chem 286 2011 31145 31152 Immunology